Regulation of soluble VEGFR-2 secreted by microvascular endothelial cells derived from human BPH

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 2, 2012, Pages 157-164

  Aweimer, A ^a   Stachon, T ^a   Tannapfel, A ^a   Koller M ^a   Truss, M C ^b   Stachon, A ^c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b KLINIKUM DORTMUND   (Germany)

^c Westpfalz Klinikum GmbH   (Germany)

Author keywords

angiogenesis; BPH; cell growth regulation; growth factors; interleukins; VEGF

Indexed keywords

ADENOSINE TRIPHOSPHATE; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROVASCULAR ENDOTHELIAL CELL; MODULATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN SECRETION;

ADENOSINE TRIPHOSPHATE; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; INTERLEUKIN-12; INTERLEUKIN-6; INTERLEUKIN-8; MALE; PROSTATE; PROSTATIC HYPERPLASIA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84861234828     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.63     Document Type: Article

References (70)

1. Lissbrant IF, Lissbrant E, Damber JE, Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001; 35: 437-452
2. Bates M, Kovalenko B,Wilson EL, Moscatelli D. Endothelial cells support the growth of prostate tissue in vivo. Prostate 2008; 68: 893-901
3. Szentirmai O, Baker CH, Bullain SS, Lin N, Takahashi M, Folkman J et al. Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation. J Neurosurg 2008; 108: 979-988
4. RisauW. Differentiation of endothelium. FASEB J 1995; 9: 926-933
5. Gerritsen ME. Functional heterogeneity of vascular endothelial cells. Biochem Pharmacol 1987; 36: 2701-2711
6. Thorin E, Shatos MA, Shreeve SM, Walters CL, Bevan JA. Human vascular endothelium heterogeneity. A comparative study of cerebral and peripheral cultured vascular endothelial cells. Stroke 1997; 28: 375-381
7. Stachon A, Schlüter T, Köller M, Weisser H, Krieg M. Primary culture of microvascular endothelial cells from human benign prostatic hyperplasia. Prostate 2001; 48: 156-164
8. Stachon A, Schlüter T, Junker K, Knopf HJ, Neuser RD, Krieg M. The secretion of endothelin-1 by microvascular endothelial cells from human benign prostatic hyperplasia is inhibited by vascular endothelial growth factor. Growth Factors 2004; 22: 281-289
9. Stachon A, Aweimer A, Stachon T, Tannapfel A, Thoms S, Ubrig B et al. Secretion of soluble VEGF receptor 2 by microvascular endothelial cells derived by human benign prostatic hyperplasia. Growth Factors 2009; 27: 71-78
10. Franck-Lissbrant I, Häggström S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139: 451-456
11. Folkman J. Editorial: Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 1998; 139: 441-442
12. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55: 15-36
13. Soltau J, Drevs J. Mode of action and clinical impact of VEGF signalling inhibitors. Expert Rev Anticancer Ther 2009; 9: 649-662
14. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G et al. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008; 68: 521-529
15. Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009; 15: 1023-1030
16. Agostini H, Boden K, Unsöld A, Martin G, Hansen L, Fiedler U et al. A single local injection of recombinant VEGF receptor 2 but not of Tie2 inhibits retinal neovascularization in the mouse. Curr Eye Res 2005; 30: 249-257
17. Bevilacqua MP, Stengelin S, Gimbrone Jr MA, Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989; 243: 1160-1165
18. Hewett PW, Murray JC. Human microvessel endothelial cells: isolation, culture and characterization. In Vitro Cell Dev Biol 1993; 29A: 823-830
19. Hahn D, Simak R, Steiner GE, Handisurya A, Susani M, Marberger M. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J Urol 2000; 164: 506-510
20. Krupski T, Harding MA, Herce ME, Gulding KM, Stoler MH, Theodorescu D. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. Growth Factors 2001; 18: 287-302
21. Hrouda D, Nicol DL, Gardiner RA. The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. Urol Res 2003; 30: 347-355
22. Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 2003; 251: 287-290
23. Campbell CL, Savarese DM, Quesenberry PJ, Savarese TM. Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: predominance of vascular endothelial growth factor. Int J Cancer 1999; 80: 868-874
24. Häggström S, Bergh A, Damber JE. Vascular endothelial growth factor content in metastasizing and nonmetastasizing dunning prostatic adenocarcinoma. Prostate 2000; 45: 42-50
25. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027
26. Shibuya M. Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 2006; 13: 63-69
27. Cébe-Suarez S, Zehnder-Fjällman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 2006; 63: 601-615
28. Ng YS, Krilleke D, Shima DT. VEGF function in vascular pathogenesis. Exp Cell Res 2006; 312: 527-537
29. Shibuya M. Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Cancer Sci 2003; 94: 751-756
30. Pradeep CR, Sunila ES, Kuttan G. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther 2005; 4: 315-321
31. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006; 39: 469-478
32. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2004; 2: 315-326
33. RoecklW, Hecht D, Sztajer H,Waltenberger J, Yayon A,WeichHA. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res 1998; 241: 161-170
34. Wierzbowska A, Robak T, Wrzesieñ-Kuoe A, Krawczyñska A, Lech-Marañda E, Urbañska-Ryoe H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw 2003; 14: 149-153
35. Pieh C, Agostini H, Buschbeck C, Krüger M, Schulte-Mönting J, Zirrgiebel U et al. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol 2008; 92: 689-693
36. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989; 3: 2007-2018
37. Janssens R, Boeynaems JM. Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells. Br J Pharmacol 2001; 132: 536-546
38. Vanoverberghe K, Mariot P, Vanden Abeele F, Delcourt P, Parys JB, Prevarskaya N. Mechanisms of ATP-induced calcium signaling and growth arrest in human prostate cancer cells. Cell Calcium 2003; 34: 75-85
39. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 2006; 58: 58-86
40. Burnstock G. Purinergic regulation of vascular tone and remodelling. Auton Autacoid Pharmacol 2009; 29: 63-72
41. Feoktistov I, Goldstein AE, Ryzhov S, Zeng D, Belardinelli L, Voyno-Yasenetskaya T et al. Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ Res 2002; 90: 531-538
42. Strasly M, Cavallo F, Geuna M, Mitola S, Colombo MP, Forni G et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 2001; 166: 3890-3899
43. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223-1230
44. Tahara H, Zeh 3rd HJ, Storkus WJ, Pappo I, Watkins SC, Gubler U et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182-189
45. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994; 153: 1697-1706
46. Sunderkötter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994; 55: 410-422
47. Sague SL, Tato C, Pur E, Hunter CA. The regulation and activation of CD44 by natural killer (NK) cells and its role in the production of IFN-gamma. J Interferon Cytokine Res 2004; 24: 301-309
48. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13: 4677-4685
49. Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000; 60: 1111-1116
50. Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 1998; 78: 361-365
51. Battle TE, Lynch RA, Frank DA. Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res 2006; 66: 3649-3657
52. Brookes PS, Salinas EP, Darley-Usmar K, Eiserich JP, Freeman BA, Darley-Usmar VM et al. Concentration-dependent effects of nitric oxide on mitochondrial permeability transition and cytochrome c release. J Biol Chem 2000; 275: 20474-20479
53. Mitchell PH, Bull K, Glautier S, Hopper NA, Holden-Dye L, O0Connor V. The concentration-dependent effects of ethanol on Caenorhabditis elegans behaviour. Pharmacogenomics J 2007; 7: 411-417
54. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003; 170: 3369-3376
55. Petreaca ML, Yao M, Liu Y, Defea K, Martins-Green M. Transactivation of vascular endothelial growth factor receptor- 2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/ CXCL8-induced endothelial permeability. Mol Biol Cell 2007; 18: 5014-5023
56. Murdoch C, Monk PN, Finn A. Cxc chemokine receptor expression on human endothelial cells. Cytokine 1999; 11: 704-712
57. Salcedo R, Resau JH, Halverson D, Hudson EA, Dambach M, Powell D et al. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J 2000; 14: 2055-2064
58. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-1801
59. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000; 6: 2104-2119
60. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-6741
61. Bancroft CC, Chen Z, Dong G, Sunwoo JB, Yeh N, Park C et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 2001; 7: 435-442
62. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 2009; 284: 6038-6042
63. Fee D, Grzybicki D, Dobbs M, Ihyer S, Clotfelter J, Macvilay S et al. Interleukin 6 promotes vasculogenesis of murine brain microvessel endothelial cells. Cytokine 2000; 12: 655-665
64. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003; 22: 1517-1527
65. Yao JS, Zhai W, Young WL, Yang GY. Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. Biochem Biophys Res Commun 2006; 342: 1396-1404
66. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone Jr MA, Libby P. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb 1994; 14: 1829-1836
67. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell Jr RP et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-1530
68. Shibata MA, Ambati J, Shibata E, Albuquerque RJ, Morimoto J, Ito Y et al. The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model. BMC Med 2010; 8: 69
69. Pavlakovic H, Becker J, Albuquerque R, Wilting J, Ambati J. Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors. Ann NY Acad Sci 2010; 1207: E7-15
70. Ruch JM, Hussain MH. Evolving therapeutic paradigms for advanced prostate cancer. Oncology (Williston Park) 2011; 25: 496-504, 508